| Sea Cliff Healthcare Center | |
| 18811 Florida St, Huntington Beach, California 92648 | |
| (714) 847-3515 | |
| Name | Sea Cliff Healthcare Center |
|---|---|
| Location | 18811 Florida St, Huntington Beach, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 182 |
| Occupancy Rate | 90.66% |
| Medicare ID (CCN) | 555249 |
| Legal Business Name | Hb Healthcare Associates Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1154316933 |
| Organization Name | HB HEALTHCARE ASSOCIATES LLC |
| Doing Business As | SEA CLIFF HEALTHCARE CENTER |
| Address | 18811 Florida St, Huntington Beach, CA 92648 |
| Phone Number | 714-847-3515 |
News Archive
Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.
In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.
TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration.
Activant Solutions Inc., a leading provider of retail and distribution business management solutions, today announced that Lifechek Drug Inc. has selected the Activant Eagle® software platform to be its business management and Point-of-Sale (POS) solution. Lifechek executives selected the Activant Eagle solution as part of a greater effort to improve and expand its front store retail business.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.
In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.
TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration.
Activant Solutions Inc., a leading provider of retail and distribution business management solutions, today announced that Lifechek Drug Inc. has selected the Activant Eagle® software platform to be its business management and Point-of-Sale (POS) solution. Lifechek executives selected the Activant Eagle solution as part of a greater effort to improve and expand its front store retail business.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 4.63 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.85 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 14.49 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.68 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.49 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.41 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.28 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.83 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.62 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.08 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.89 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.75 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.83 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.07 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.12 | 82.93 |
News Archive
Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.
In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.
TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration.
Activant Solutions Inc., a leading provider of retail and distribution business management solutions, today announced that Lifechek Drug Inc. has selected the Activant Eagle® software platform to be its business management and Point-of-Sale (POS) solution. Lifechek executives selected the Activant Eagle solution as part of a greater effort to improve and expand its front store retail business.
› Verified 6 days ago
Huntington Valley Healthcare Center Location: 8382 Newman Avenue, Huntington Beach, California 92647 Phone: (714) 842-5551 | |
Beachside Nursing Center Location: 7781 Garfield Avenue, Huntington Beach, California 92648 Phone: (714) 847-9671 | |
Sea Cliff Healthcare Center Location: 18811 Florida St, Huntington Beach, California 92648 Phone: (714) 847-3515 |